Mode
Text Size
Log in / Sign up

Individualized treatment planning for synchronous bilateral primary breast cancer is supported by independent lesion characterizationIndividualized treatment plans help patients with dual primary breast cancers

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider independent characterization of each lesion to guide individualized treatment for synchronous bilateral primary breast cancer.

This publication is a case report and literature review focusing on patients with synchronous bilateral primary breast cancer (sBPBC). The scope includes an analysis of 1 reported case and 7 cases from existing literature to evaluate clinicopathological characteristics, molecular profiles, and treatment strategies.

The authors identify considerable heterogeneity in molecular profiles, nodal involvement, and clinical outcomes among patients with sBPBC. In the reported case, a 12-month follow-up showed no recurrence or metastasis following bilateral breast-conserving surgery, sentinel lymph node biopsy, adjuvant radiotherapy, and endocrine therapy. The review emphasizes that because each breast lesion may possess distinct characteristics, independent characterization of each tumor is essential for developing individualized treatment plans.

A primary limitation of this evidence is the small sample size, consisting of only 8 total cases. The findings are based on a case report and a limited literature review rather than a large-scale clinical trial. Clinical application is currently limited by the small cohort, but the findings support the necessity of tailored management for sBPBC based on the specific features of both tumors.

How this fits prior evidence

This report addresses a gap in the management of complex presentations of breast cancer. While prior coverage noted that HR-positive HER2-low breast cancer accounts for 60% of cases and may require endocrine therapy and CDK4/6 inhibitors, this review specifically addresses the management of synchronous bilateral primary breast cancer. It supports the need for individualized treatment planning based on the specific features of both tumors, which may differ significantly in molecular profiles and clinical outcomes.

When a patient is diagnosed with cancer in both breasts at the same time, doctors face a complex challenge. They must decide how to treat two different tumors that may have different characteristics. This study looks at cases where patients had these dual primary breast cancers, known as sBPBC.

Researchers reviewed a specific case and seven others in medical literature. They found that these tumors vary significantly in their molecular profiles and how they behave. Because each tumor can be different, the study suggests that doctors should treat each breast lesion as its own unique case. This allows for a more personalized treatment plan for the patient.

While the results for the cases reviewed were positive, it is important to note that the study size is very small. It only looked at one specific case and a small group of others. Because of this limited number of cases, the findings are not enough to set a universal rule, but they do highlight the importance of tailoring care to the specific features of each tumor.

What this means for you:
Treating each breast tumor as a unique case helps doctors create more personalized plans for patients with dual cancers.

Common questions

What is the benefit of treating each breast tumor individually?

Because tumors can have different molecular profiles and characteristics, treating each one as a unique case allows doctors to create a personalized treatment plan. This approach focuses on the specific features of both tumors to better manage the patient's health.

How many cases were included in this study?

The report included one specific case and a review of seven other cases in the literature. Because this is a small sample size, the findings are not from a large-scale clinical trial.

What were the outcomes for the patients in this report?

In the cases reviewed, no recurrence or metastasis was observed during the follow-up period. However, the study notes that there was a lot of variety in the types of tumors and treatment strategies used.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedOct 2026
View Original Abstract ↓
Synchronous bilateral primary breast cancer (sBPBC) accounts for 2.9%–3.9% of newly diagnosed breast cancers, while cases with discordant histologic subtypes are exceptionally rare. We report on a 59-year-old woman with synchronous left-sided invasive ductal carcinoma (IDC) and right-sided invasive lobular carcinoma (ILC). The patient underwent bilateral breast-conserving surgery with sentinel lymph node biopsy, followed by adjuvant radiotherapy and endocrine therapy. No recurrence or metastasis was observed during the 12-month follow-up. To place the present case in the context of the existing literature, we comparatively reviewed seven previously reported cases of synchronous bilateral IDC and ILC. The comparison illustrated considerable heterogeneity in the clinicopathological characteristics, molecular profiles, nodal involvement, treatment strategies, and clinical outcomes. These findings support independent characterization of each breast lesion and individualized treatment planning based on the features of both tumors.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.